Efficacy of topical recombinant human platelet-derived growth factor for treatment of diabetic lower-extremity ulcers: Systematic review and meta-analysis
Authors:
- 1 October 2014
- journal article
- review article
- Published by Elsevier in Metabolism
- Vol. 63 (10) , 1304-1313
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- The Evidence for the Use of Growth Factors and Active Skin Substitutes for the Treatment of Non-Infected Diabetic Foot Ulcers (DFU): A Health Technology Assessment (HTA)Experimental and Clinical Endocrinology & Diabetes, 2011
- Formulated collagen gel accelerates healing rate immediately after application in patients with diabetic neuropathic foot ulcersWound Repair and Regeneration, 2011
- Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcersIndian Journal of Surgery, 2010
- Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcersBMC Health Services Research, 2009
- Management and Prevention of Diabetic Foot Ulcers and InfectionsPharmacoEconomics, 2008
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcersExpert Opinion on Biological Therapy, 2002
- Recombinant human platelet‐derived growth factor‐BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open‐label clinical evaluation of efficacyWound Repair and Regeneration, 2000
- Efficacy and Safely of a Topical Gel Formulation of Recombinant Human Platelet-Derived Growth Factor-BB (Becaplermin) in Patients With Chronic Neuropathic Diabetic Ulcers: A phase III randomized placebo-controlled double-blind studyDiabetes Care, 1998
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986